Amplification of EZH2 in CML LSCs and reduction after TKI therapy shows its engagement in the pathogenesis of CML and its dependency on BCR-ABL1 TK activity. This evidence concerns the gene EZH2 and chronic myelogenous leukemia, BCR-ABL1 positive.